See more : Northern Region Cement Company (3004.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Rigel Pharmaceuticals, Inc. (RIGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rigel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Merus N.V. (MRUS) Income Statement Analysis – Financial Results
- Sterling Metals Corp. (SAG.V) Income Statement Analysis – Financial Results
- CS Holdings Co., Ltd. (000590.KS) Income Statement Analysis – Financial Results
- Rovio Entertainment Oyj (RVTTY) Income Statement Analysis – Financial Results
- Nyrada Inc. (NYR.AX) Income Statement Analysis – Financial Results
Rigel Pharmaceuticals, Inc. (RIGL)
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M | 28.90M | 8.25M | 7.15M | 2.25M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 13.22M | 8.98M |
| Cost of Revenue | 7.11M | 1.75M | 1.08M | 895.00K | 906.00K | 287.00K | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.56M | -1.91M |
| Gross Profit | 109.77M | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M | -41.79M | -43.06M | -33.93M | -59.45M | -68.18M | -76.53M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 20.78M | 10.89M |
| Gross Profit Ratio | 93.92% | 98.55% | 99.27% | 99.18% | 98.47% | 99.36% | -931.87% | -211.27% | -117.43% | -720.56% | -953.54% | -3,401.24% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 157.17% | 121.22% |
| Research & Development | 24.52M | 60.27M | 65.24M | 60.10M | 52.89M | 46.90M | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 69.35M | 64.39M | 90.74M | 109.67M | 70.36M | 56.97M | 52.04M | 48.52M | 43.36M | 43.35M | 32.31M | 32.03M | 17.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 105.74M | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 3.95M |
| Other Expenses | 0.00 | 1.32M | 3.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.56M | 1.91M |
| Operating Expenses | 130.26M | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 46.28M | 22.97M |
| Cost & Expenses | 137.37M | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 38.72M | 21.06M |
| Interest Income | 2.27M | 684.00K | 47.00K | 582.00K | 2.53M | 2.20M | 892.00K | 437.00K | 222.00K | 243.00K | 442.00K | 537.00K | 420.00K | 303.00K | 600.00K | 4.44M | 5.48M | 5.70M | 2.94M | 966.00K | 374.00K | 856.00K | 1.96M | 1.08M | 0.00 |
| Interest Expense | 6.87M | 3.71M | 4.86M | 1.35M | 335.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 17.00K | 25.00K | 91.00K | 203.00K | 160.00K | 221.00K | 290.00K | 276.00K | 324.00K | 575.00K | 870.00K | 802.00K | 933.00K | 0.00 |
| Depreciation & Amortization | 1.24M | 998.00K | 1.16M | 706.00K | 683.00K | 594.00K | 465.00K | 941.00K | 1.44M | 2.36M | 2.59M | 2.43M | 1.96M | 1.32M | 1.40M | 1.43M | 1.34M | 1.42M | 1.18M | 2.37M | 3.18M | 5.82M | 6.76M | 7.56M | 1.91M |
| EBITDA | -16.98M | -53.87M | -11.29M | -27.69M | -65.88M | -69.89M | -77.53M | -63.03M | -50.30M | -88.89M | -85.20M | -96.94M | -83.99M | 39.30M | -110.03M | -130.85M | -79.53M | -43.05M | -47.92M | -54.49M | -37.65M | -31.19M | -18.20M | -17.95M | -10.17M |
| EBITDA Ratio | -14.53% | -44.53% | -5.98% | -26.14% | -112.26% | -163.30% | -1,791.88% | -285.97% | -179.27% | -1,107.24% | -1,185.40% | -4,416.76% | -1,768.27% | 29.55% | -14,519.07% | 0.00% | -620.50% | -124.37% | -282.84% | -1,150.73% | -339.04% | -197.57% | -118.93% | -135.78% | -113.25% |
| Operating Income | -20.49M | -54.23M | -8.98M | -28.97M | -69.09M | -72.68M | -79.62M | -69.74M | -51.74M | -91.25M | -89.47M | -99.38M | -86.37M | 35.32M | -112.04M | -136.71M | -79.53M | -43.05M | -47.92M | -56.87M | -40.83M | -37.02M | -24.96M | -25.51M | -12.08M |
| Operating Income Ratio | -17.53% | -45.10% | -6.01% | -26.67% | -116.53% | -163.30% | -1,775.56% | -342.15% | -179.07% | -1,106.05% | -1,251.31% | -4,416.76% | -1,818.27% | 28.25% | -14,938.27% | 0.00% | -631.17% | -128.60% | -289.98% | -1,201.50% | -369.31% | -234.46% | -163.11% | -192.96% | -134.46% |
| Total Other Income/Expenses | -4.60M | -3.02M | -4.81M | -771.00K | 2.20M | 2.20M | 1.62M | 525.00K | 279.00K | 341.00K | 442.00K | 537.00K | 395.00K | 2.57M | 397.00K | 4.28M | 5.26M | 5.41M | 2.67M | 612.00K | -370.00K | -14.00K | 1.16M | 145.00K | 0.00 |
| Income Before Tax | -25.09M | -58.57M | -17.31M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.64M | -132.44M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | 0.00 |
| Income Before Tax Ratio | -21.47% | -48.71% | -11.60% | -27.38% | -112.83% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,885.33% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | 0.00% |
| Income Tax Expense | 0.00 | 3.02M | 605.00K | 647.00K | -348.00K | 2.20M | -2.09M | 4.30M | -1.72M | -2.70M | 0.00 | -2.43M | 420.00K | 91.00K | -93.00K | -89.00K | 0.00 | 0.00 | 0.00 | -612.00K | 370.00K | 0.00 | 0.00 | 0.00 | 286.00K |
| Net Income | -25.09M | -61.60M | -17.91M | -30.39M | -66.55M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.55M | -132.35M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | -12.37M |
| Net Income Ratio | -21.47% | -51.23% | -12.00% | -27.98% | -112.24% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,872.93% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | -137.64% |
| EPS | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.73 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| EPS Diluted | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.72 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| Weighted Avg Shares Out | 17.40M | 17.24M | 17.05M | 16.88M | 16.72M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.88M | 63.33M | 52.06M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
| Weighted Avg Shares Out (Dil) | 17.40M | 17.24M | 17.05M | 16.88M | 16.74M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.97M | 63.33M | 52.57M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
New Strong Buy Stocks for November 22nd
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Call Transcript
Rigel to Present at the Jefferies London Healthcare Conference
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
Rigel Announces Presentation at the Upcoming IDWeek 2023
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel to Present at the 2023 Cantor Global Healthcare Conference
Rigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports